<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83883">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013271</url>
  </required_header>
  <id_info>
    <org_study_id>CL0017-01</org_study_id>
    <nct_id>NCT02013271</nct_id>
  </id_info>
  <brief_title>Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries</brief_title>
  <official_title>A Prospective, Multicenter, Single-Arm Trial With the Lutonix Drug Coated Balloon for Treatment of Long Lesions in Femoropopliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate efficacy and safety of the Lutonix® Drug Coated Balloon for treatment of long
      TASC II Class C and D lesions (≥ 14 cm) lesions in the SFA
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Composite of freedom from all-cause periprocedural death and freedom at 1 year from the following: index limb amputation (above or below the ankle) and index limb re-intervention.</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Primary Patency</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Major vascular complications (≤30 day)</measure>
    <time_frame>1, 6, 12, 24, 36 months</time_frame>
    <description>Composite Safety (criteria of the primary endpoint)
All-cause death
Amputation (major and minor separately)
Target Vessel Revascularization (TVR)
Target Limb Reintervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Acute Device, Technical and Procedural success</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>The following endpoints will be assessed at 6, 12 and 24 Months:
Primary and Secondary Patency
Target Lesion Revascularization (TLR)
Clinically-driven
Total (clinical and DUS/angiography-driven)
Change of Rutherford classification from baseline
Change of resting Ankle Brachial Index (ABI) from baseline
Change in Walking Impairment Questionnaire from baseline
Change in quality of life from baseline, as measured by EQ-5D</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Femoral Artery Occlusion</condition>
  <condition>Femoral Arterial Stenosis</condition>
  <arm_group>
    <arm_group_label>Lutonix DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lutonix Paclitaxel Drug Coated Balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix Paclitaxel Drug Coated Balloon</intervention_name>
    <arm_group_label>Lutonix DCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical Criteria

          1. ≥ 18 years of age;

          2. Rutherford Clinical Category 2-4;

          3. Subject is legally competent and voluntarily agrees to participation and the study's
             provisions; is willing to provide 5-year informed consent;

          4. ≥ 70% stenosis of a native femoropopliteal artery (by visual estimate) that is
             amenable to DCB with or without stenting;

          5. TASC II Class C or D Lesions with intended target lesion treatment segment(s)
             cumulatively ≥14 cm in length;

          6. de novo lesion(s) or non-stented restenotic lesion(s) &gt; 90 days from prior
             angioplasty procedure;

          7. Target vessel diameter between ≥ 4 and ≤ 7 mm;

          8. Successful wire crossing of lesion and predilatation;

          9. No other prior vascular interventions (including contralateral limb) within 2 weeks
             before and/or planned 30 days after the protocol treatment.

        Exclusion Criteria:

          1. Women who are pregnant, lactating, or planning on becoming pregnant or men intending
             to father children;

          2. Patient is contraindicated to use Lutonix Drug Coated Balloon per the current
             Instructions For Use (IFU);

          3. Life expectancy of &lt; 1year;

          4. Patient is currently participating in an investigational drug or other device study
             or previously enrolled in this study;

          5. History of stroke within 3 months;

          6. History of myocardial infarction, thrombolysis or angina within 2 weeks of
             enrollment;

          7. Prior vascular surgery of index limb with exception of endarterectomy or remote
             common femoral patch angioplasty;

          8. Target lesion involves a previously placed stent;

          9. Inability to take required study medications or allergy to contrast that cannot be
             adequately managed with pre- and post-procedure medication;

         10. Significant inflow disease;

         11. Known inadequate distal outflow or planned future treatment of vascular disease;

         12. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute angiographically
             visible thrombus in target vessel;

         13. Use of adjunctive treatment modalities (e.g. laser, atherectomy or cryoplasty)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Banyai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital Lucerne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Eric Ducasse, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA-Campus Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZA Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Talence cedex</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev.Krankenhaus Königin Elisabeth</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfälische Wilhelms-Universität Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Osnabrück</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medinos Kliniken Sonneberg</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital, Division of Angiology</name>
      <address>
        <city>Lucerne</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 7, 2016</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
